Sutro Biopharma, Inc. · NASDAQ:STRO

Sutro Biopharma — 21st Annual Needham Virtual Healthcare Conference 2022

25 slides from Sutro Biopharma's conference presentation, April 2022

  1. Slide 1: 21st Annual Needham Virtual Healthcare Conference

    21st Annual Needham Virtual Healthcare Conference April 2022 Sutro Biopharma NASDAQ: STRO NON-CONFIDENTIAL

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state

  3. Slide 3: Drug Discovery Platform Enables the Potential for Best-in-Class Molecules

    Drug Discovery Platform Enables the Potential for Best-in-Class Molecules Precise novel design to enhance efficacy and safety across multiple modalities and targets Cytokine Derivative Conjugated Antibody Bispecific Antibody Prodrug Cytokine ADC or ISAC iADC Modality Bispecific ADC Immune Cell Engag

  4. Slide 4: Robust Pipeline through Wholly-Owned and Partnered Programs

    Robust Pipeline through Wholly-Owned and Partnered Programs Five product candidates advancing in the clinic and late-stage discovery programs Modality Program Target Indication Discovery Preclinical Phase 1/1b Phase 2/3 Partner Ovarian Cancer Fast Track Designation Ovarian Cancer (bevacizumab combo)

  5. Slide 5: Achievements and Milestones

    Achievements and Milestones Clinical data readouts and partnerships provide multiple 2022 value drivers for Sutro STRO-002, FolRα ADC STRO-001, CD74 ADC ✓ Greater China deal with Tasly (Dec. 2021) ✓ Greater China deal with BioNova (Oct. 2021) Support BioNova for initiation of clinical development ✓

  6. Slide 6: FolRα-Targeting ADC

    STRO 002 FolRα-Targeting ADC Potential Best-in-Class ADC for Ovarian Cancer NON-CONFIDENTIAL

  7. Slide 7: Highly optimized ADC designed to drive efficient tumor responses across a broad range of target antigen levels

    Highly optimized ADC designed to drive efficient tumor responses STRO 002 across a broad range of target antigen levels 1 FolRα STRO-002 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 4, targeting folate-receptor alpha (FolRα) Y180 1 FolRα is overexpressed in cert

  8. Slide 8: Phase 1 Study in Patients with Advanced Ovarian Cancer

    STRO 002 Phase 1 Study in Patients with Advanced Ovarian Cancer Two-part design to explore safety, anti-tumor activity, dosing, and FolRα enrichment strategy Part 1: Dose-Escalation Cohort Part 2: Dose-Expansion Cohort Protocol Inclusive of all FolRα expression levels; tissue samples Inclusive of al

  9. Slide 9: Patient Characteristics in Dose Expansion Cohort

    STRO 002 Patient Characteristics in Dose Expansion Cohort Dose Expansion Interim data for dose expansion are as of November 8, 2021 Patient Baseline Characteristics Patient Status as of November 8, 2021 Randomized Dose Levels Total Patients Enrolled Total N=44 Ovarian Cancer 4.3 mg/kg 5.2 mg/kg N=43

  10. Slide 10: Dose Response Demonstrated

    STRO 002 Dose Response Demonstrated Dose Expansion Interim data suggest that 5.2 mg/kg starting dose leads to higher response rates Maximum Change in Tumor Target Lesions (N=33) 20% PRu* PRu PRu* PR PR PR PR PRu* PRu* PR PR PR 2 pts had 0% Δ Partial Response -30% Treatment ongoing Starting Dose, Q3W

  11. Slide 11: STRO-002 Objective Response by RECIST v1.1

    STRO 002 Objective Response by RECIST v1.1 Dose Expansion 33% ORR rate in all 33 evaluable patients, unenriched for FolRα expression Starting Dose Best Overall Response (BOR) 4.3 mg/kg 5.2 mg/kg All Comers • 47.1% ORR in patients starting at the 5.2 mg/kg dose level Evaluable patients N=16 N=17 N=33

  12. Slide 12: Robust Anti-tumor Activity and Disease Control Demonstrated

    STRO 002 Robust Anti-tumor Activity and Disease Control Demonstrated Dose Expansion Responders experienced rapid tumor reduction or a steady deepening of response Change in Sum of Diameters for Target Lesions Over Time (N=33) Starting Dose, Q3W 4.3 mg/kg Change from baseline (%) 5.2 mg/kg Treatment

  13. Slide 13: Encouraging Response Rates and Preliminary Data on Durability

    STRO 002 Encouraging Response Rates and Preliminary Data on Durability Dose Expansion Interim data suggest initiating with 5.2 mg/kg followed by a dose adjustment Treatment Duration on Patients with at Least One Dose (N=43) Initial data show partial responses confirmed & Individual patients treated

  14. Slide 14: Platinum-Resistant Ovarian Cancer Patient Treated at 4.3 mg/kg Dose Level

    STRO 002 Platinum-Resistant Ovarian Cancer Patient Treated at 4.3 mg/kg Dose Level Dose Expansion Ongoing Partial Response with 72% reduction in tumor burden Initial diagnosis: Stage IV Lateral Abdominal Wall Axillary Lymph Node Inter-aortocaval LN External Iliac LN ovarian cancer, Jan 2020 3 Prior

  15. Slide 15: TPS Identified as Scoring Algorithm Appropriate for STRO-002

    STRO 002 TPS Identified as Scoring Algorithm Appropriate for STRO-002 Dose Expansion Exploratory analysis suggests TPS > 25% correlated with higher response ORR by TPS Expression Levels (Total Samples N=33) TPS TPS TPS TPS TPS Overall ≤ 25% > 25% > 50% > 75% Tumor Proportion Score (TPS) ORR 33.3% 12

  16. Slide 16: Emerging Safety Profile is Manageable – 85.5% of TEAEs were Grade 1-2

    STRO 002 Emerging Safety Profile is Manageable – 85.5% of TEAEs were Grade 1-2 Dose Expansion No new safety signals were observed, including the absence of keratopathy Most Common G3+ TEAEs (≥2 Subjects) by Dose 4.3 mg/Kg (N=23) 5.2 mg/Kg (N=20) Total (N=43) Asymptomatic neutropenia Grade 3 Grade 4

  17. Slide 17: Dose Expansion Interim Data Provide Initial Insights on Go-Forward Strategy

    STRO 002 Dose Expansion Interim Data Provide Initial Insights on Go-Forward Strategy Dose Expansion Emerging data inform potential starting dose and enrichment strategy Overall Efficacy Dose Response Biomarker Safety Total of 11 confirmed PR (1) 47% ORR (8/17) in Interim data suggest TPS > No new sa

  18. Slide 18: Progressing & Expanding the STRO-002 Franchise

    STRO 002 Progressing & Expanding the STRO-002 Franchise Additional clinical studies in ovarian & endometrial, and nonclinical work on other tumor types Ovarian Cancer Combo study with bevacizumab Trial is open and enrolling patients FPI March 2022 Dose-escalation cohort Dose-expansion cohort Registr

  19. Slide 19: CD74-Targeting ADC

    STRO 001 CD74-Targeting ADC Potential First and Best-in-Class ADC for B-Cell Malignancies NON-CONFIDENTIAL

  20. Slide 20: Potential First-in-Class Molecule for Patients with NHL and MM

    STRO001 STRO 001 Potential First-in-Class Molecule for Patients with NHL and MM Stable CD74 targeting ADC for hematological cancers designed to minimize bystander effects 1 CD74 STRO-001 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 2, targeting CD74: 1 CD74 is e

  21. Slide 21: STRO-001-BCM1 Study Design and Updates

    STRO001 STRO 001 STRO-001-BCM1 Study Design and Updates Ongoing Phase 1 dose escalation study with NHL update at ASH 2020 STRO-001-BCM1 Dose Escalation Study NHL Cohort Update at ASH 2020 R/R multiple myeloma Cohort A RP2D A total of 21 patients have been treated with (N=30) STRO-001 and 18 patients

  22. Slide 22: ASH 2020 Update in NHL Cohort

    STRO 001 ASH 2020 Update in NHL Cohort Heavily pre-treated patient population with 5 median lines of prior therapies Baseline Characteristic (N=21) TEAEs by Grade, Patients With ≥1 Event, n (%) Age, median (range), years 64.5 (21–82) Occurring in ≥15% Grade 1 Grade 2 Grade 3 Grade 4 Time from diagno

  23. Slide 23: Encouraging Interim Treatment Duration and Responses

    STRO 001 Encouraging Interim Treatment Duration and Responses Partial responses in two DLBCL patients who had progressed on CAR-T Treatment Duration Responses to STRO-001 SD* Dose Best Doses Duration of Demographics and Level, Prior Therapies PR Diagnosis Responses Received Treatment Individual pati

  24. Slide 24: Financial Overview

    Financial Overview Well-capitalized through cash and other financial sources $229.5M Projected cash runway into in cash, cash equivalents & 2H 2023(1), marketable securities based on current business plans and as of Dec. 31, 2021 assumptions ~1.6M shares Funding received from our collaborators of of

  25. Slide 25: Experienced Leadership Team

    Experienced Leadership Team William Newell, JD Trevor Hallam, PhD Arturo Molina, Ed Albini, MBA Chief Executive Officer and President of Research and MD, MS, FACP Chief Financial Officer Member of the Board of Chief Scientific Officer Chief Medical Officer Directors Jane Chung, RPh Shabbir Anik, PhD

Sutro Biopharma — 21st Annual Needham Virtual Healthcare Conference 2022 on 6ix